AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31524161 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (standard e-reader)
Number of subjects: 20
Study 28234053 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 671800 200 mg twice daily with fluticasone propionate
Number of subjects: 108
Study 28234053 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 671800 400 mg A.M. with fluticasone propionate
Number of subjects: 108
Study 28234053 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 671800 400 mg P.M. with fluticasone propionate
Number of subjects: 108
Study 28234053 — intervention group
Group type: COMPARATOR
Intervention: Placebo with fluticasone propionate
Number of subjects: 108
Study 25980351 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy (cART)
Number of subjects: 0
Study 24010986 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride with 1:200,000 epinephrine (single buccal injection)
Number of subjects: 200
Study 24010986 — intervention group
Group type: COMPARATOR
Intervention: Control group received a single buccal injection and a single palatal injection before extraction
Number of subjects: 200
Study 19725894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 197
Study 19725894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 17278938 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise of moderate to high intensity
Number of subjects: 0
Study 17278938 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 15883638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (10 mg/m2/day IV for 3 days every 3 months)
Number of subjects: 18
Study 15883638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 18
Study 15883638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamidronate)
Number of subjects: 18
Study 12154425 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided double-lumen tube (DLT) insertion using the best regression line
Number of subjects: 240
Study 12154425 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided double-lumen tube (DLT) insertion verified using fiberoptic bronchoscopy
Number of subjects: 240
Study 10190878 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillators
Number of subjects: 4595
Study 7768075 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine 4.5 gm 7‐day loading dose regimen
Number of subjects: 20
Study 2138683 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins plus 75 mg diclofenac
Number of subjects: 123
Study 2138683 — intervention group
Group type: COMPARATOR
Intervention: 75 mg diclofenac alone
Number of subjects: 123
Study 7459427 — intervention group
Group type: EXPERIMENTAL
Intervention: U.K. sales tablet
Number of subjects: 12
Study 7459427 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablet formulations
Number of subjects: 12
Study 7459427 — intervention group
Group type: COMPARATOR
Intervention: Aqueous solution
Number of subjects: 12
Study 31454169 — intervention group
Group type: EXPERIMENTAL
Intervention: Health messages
Number of subjects: 207
Study 31454169 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being messages
Number of subjects: 207
Study 31780640 — intervention group
Group type: EXPERIMENTAL
Intervention: RER (imaginal retraining with electronic reminders)
Number of subjects: 384
Study 31780640 — intervention group
Group type: EXPERIMENTAL
Intervention: RS (standard retraining without electronic reminders)
Number of subjects: 384
Study 31780640 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 384
Study 31780640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both retraining groups (RER and RS)
Number of subjects: 384
Study 28041599 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg of fermented soy containing 10mg of equol and 25mg of resveratrol (1 tablet/day)
Number of subjects: 60
Study 25019600 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity in Rheumatoid Arthritis (PARA) coaching program
Number of subjects: 0
Study 25019600 — intervention group
Group type: COMPARATOR
Intervention: Ordinary physiotherapy
Number of subjects: 0
Study 23963546 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 80/5 mg
Number of subjects: 564
Study 23963546 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 30 mg
Number of subjects: 564
Study 20409576 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 3
Study 20409576 — intervention group
Group type: COMPARATOR
Intervention: Neutral affect
Number of subjects: 3
Study 20157862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral social skills training (CBSST)
Number of subjects: 62
Study 20157862 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 62
Study 17877953 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 17877953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 15753494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg(‐1), remifentanil 2 mug.kg(‐1), propofol 2 mg.kg(‐1) (Group P)
Number of subjects: 76
Study 15753494 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.5 mg.kg(‐1), remifentanil 2 mug.kg(‐1), thiopental 5 mg.kg(‐1) (Group T)
Number of subjects: 76
Study 15753494 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P
Number of subjects: 76
Study 11791811 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology foot massage
Number of subjects: 34
Study 11791811 — intervention group
Group type: COMPARATOR
Intervention: Non-reflexology foot massage (control)
Number of subjects: 34
Study 9834264 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (NG‐monomethyl‐L‐arginine), a specific NO synthase blocker
Number of subjects: 16
Study 9834264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 8594676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot-blot enzyme-linked immunosorbent assay (dot-ELISA)
Number of subjects: 121
Study 8594676 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex agglutination (LA)
Number of subjects: 121
Study 8594676 — intervention group
Group type: COMPARATOR
Intervention: Weil-Felix OX-19 test
Number of subjects: 121
Study 2548548 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study 2548548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 974527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 27
Study 974527 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortography
Number of subjects: 27
Study 974527 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocortical scintigraphy
Number of subjects: 27
Study 28622155 — intervention group
Group type: EXPERIMENTAL
Intervention: Documents with video message/testimonial (VM)
Number of subjects: 85
Study 28622155 — intervention group
Group type: COMPARATOR
Intervention: Documents only (Control)
Number of subjects: 85
Study 28622155 — intervention group
Group type: EXPERIMENTAL
Intervention: Documents with VM
Number of subjects: 85
Study 31751782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU monthly)
Number of subjects: 5110
Study 31751782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Alpha threshold of 0.05
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Power calculation
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Main hypothesis p value < 0.005
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Main hypothesis p value between 0.005 and 0.05
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Main hypothesis p value > 0.05
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Smallest p value between 0.05 and 0.005
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Smallest p value < 0.005
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Smallest p value not provided or > 0.05
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Cohort and database papers with main hypothesis p value < 0.005
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials with main hypothesis p value < 0.005
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Articles reporting power calculation with p value < 0.005
Number of subjects: 200
Study 31283730 — intervention group
Group type: COMPARATOR
Intervention: Articles not reporting power calculation with p value < 0.005
Number of subjects: 200
Study 29199184 — intervention group
Group type: EXPERIMENTAL
Intervention: scoliosis specific exercises (SSE) on a side‐alternating whole body vibration platform (sWBV) as a home‐training program for six months, five times per week.
Number of subjects: 40
Study 29199184 — intervention group
Group type: COMPARATOR
Intervention: Regular scoliosis specific exercises (SSE) as treatment as usual.
Number of subjects: 40
Study 27410480 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 218
Study 27410480 — intervention group
Group type: COMPARATOR
Intervention: Ad-libitum (AL) diet
Number of subjects: 218
Study 25342183 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing (FB) CT
Number of subjects: 52
Study 25342183 — intervention group
Group type: COMPARATOR
Intervention: Expiratory breath-hold (BH) CT
Number of subjects: 52
Study 21687997 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement frequency at 1.33 Hz
Number of subjects: 7
Study 21687997 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement frequency at 1.67 Hz
Number of subjects: 7
Study 21687997 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement frequency at 1.84 Hz
Number of subjects: 7
Study 21687997 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement frequency at 2.00 Hz
Number of subjects: 7
Study 21687997 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher movement frequencies (1.67 Hz, 1.84 Hz, 2.00 Hz)
Number of subjects: 7
Study 21687997 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MG and SOL
Number of subjects: 7
Study 19237981 — intervention group
Group type: COMPARATOR
Intervention: Propofol induction in cannabis users (group C)
Number of subjects: 60
Study 19237981 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction in nonusers (group NC)
Number of subjects: 60
Study 19237981 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction in both groups
Number of subjects: 60
Study 17472181 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primers as bonding agents underneath the composite resin restorations
Number of subjects: 80
Study 17472181 — intervention group
Group type: COMPARATOR
Intervention: Other treatment protocols (not specified)
Number of subjects: 80
Study 15853959 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once-daily
Number of subjects: 177
Study 15853959 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 177
Study 12064269 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy body mass index
Number of subjects: 188
Study 12064269 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 188
Study 12064269 — intervention group
Group type: COMPARATOR
Intervention: Maternal age
Number of subjects: 188
Study 12064269 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy weight gain
Number of subjects: 188
Study 10468096 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pericardial effusion
Number of subjects: 79
Study 10468096 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger pericardial effusion
Number of subjects: 79
Study 8562975 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 320 mg/day
Number of subjects: 11
Study 8562975 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate treatment
Number of subjects: 11
Study 8562975 — intervention group
Group type: COMPARATOR
Intervention: Cytokine production by peripheral blood lymphocytes
Number of subjects: 11
Study 2235226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for 7 days, followed by hydrocortisone 8 mg/kg per day for 10 days)
Number of subjects: 23
Study 760755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin (2.5 mg and 5 mg) in non-dependent subjects
Number of subjects: 0
Study 760755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin (1/6, 1/3, and 1/2 of prescribed doses) in dependent subjects
Number of subjects: 0
Study 760755 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent oral methadone medication with heroin
Number of subjects: 0
Study 31843975 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor 50 U/kg
Number of subjects: 70
Study 31843975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30603015 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF ratio ≥0.9 before extubation
Number of subjects: 168
Study 30603015 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment of return of neuromuscular function
Number of subjects: 168
Study 27278922 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 174
Study 27278922 — intervention group
Group type: COMPARATOR
Intervention: NPH/Reg
Number of subjects: 174
Study 24737258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (200,000 IU) administered intravenously 12 hourly for 5 days
Number of subjects: 122
Study 24737258 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously 12 hourly for 5 days
Number of subjects: 122
Study 22696608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mode weaning (n = 15)
Number of subjects: 32
Study 20414709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min infusion of 2 mg/kg of propofol
Number of subjects: 21
Study 20414709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min infusion of 2 mg/kg of propofol followed by a 29 min infusion of 12 mg kg(‐1) h(‐1) of propofol
Number of subjects: 21
Study 17955229 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tizanidine (in nonsmokers)
Number of subjects: 71
Study 17955229 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tizanidine (in male smokers)
Number of subjects: 71
Study 17955229 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine test (in male smokers)
Number of subjects: 71
Study 17955229 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tizanidine (in females)
Number of subjects: 71
Study 16477807 — intervention group
Group type: EXPERIMENTAL
Intervention: High stearic acid diet (shea butter)
Number of subjects: 0
Study 16477807 — intervention group
Group type: EXPERIMENTAL
Intervention: High stearic acid diet (synthesized test fat)
Number of subjects: 0
Study 16477807 — intervention group
Group type: COMPARATOR
Intervention: High trans and oleic FA
Number of subjects: 0
Study 12211509 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimistically slanted information tape
Number of subjects: 296
Study 12211509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape featuring coping with more ups and downs
Number of subjects: 296
Study 12211509 — intervention group
Group type: COMPARATOR
Intervention: No tape at all (control group)
Number of subjects: 296
Study 10431125 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher incentive plus reminder-recall
Number of subjects: 565
Study 10431125 — intervention group
Group type: COMPARATOR
Intervention: Voucher incentive alone
Number of subjects: 565
Study 8701878 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8701878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1681044 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% alpha-linolenic acid in intravenous lipids
Number of subjects: 0
Study 1681044 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk feeding
Number of subjects: 0
Study 1681044 — intervention group
Group type: COMPARATOR
Intervention: 4.2% alpha-linolenic acid in intravenous lipids
Number of subjects: 0
Study 1681044 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0
Study 1681044 — intervention group
Group type: COMPARATOR
Intervention: Premature milk formula (Preemie Enfamil)
Number of subjects: 0
Study 6636913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP) parenteral application (s.c., i.m., i.v.)
Number of subjects: 10
Study 6636913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP)
Number of subjects: 10
Study 31794244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 168
Study 31794244 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 168
Study 31794244 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Methylphenidate and Atomoxetine
Number of subjects: 168
Study 31068225 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted cognitive behavioural therapy for insomnia (PA-CBTI)
Number of subjects: 120
Study 31068225 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional individual cognitive behavioural therapy for insomnia (i-CBTI)
Number of subjects: 120
Study 31068225 — intervention group
Group type: COMPARATOR
Intervention: Partner-assisted sleep management therapy (PA-SMT)
Number of subjects: 120
Study 27734232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 797
Study 27734232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 797
Study 27734232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study 27401980 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes
Number of subjects: 105
Study 27401980 — intervention group
Group type: EXPERIMENTAL
Intervention: dual users (substituted half of daily cigarette consumption with e-cigarettes)
Number of subjects: 105
Study 27401980 — intervention group
Group type: COMPARATOR
Intervention: cessation (discontinued all nicotine and tobacco products)
Number of subjects: 105
Study 27401980 — intervention group
Group type: COMPARATOR
Intervention: dual users
Number of subjects: 105
Study 27401980 — intervention group
Group type: EXPERIMENTAL
Intervention: all groups
Number of subjects: 105
Study 27401980 — intervention group
Group type: EXPERIMENTAL
Intervention: cessation and e-cigarette use groups
Number of subjects: 105
Study 24637282 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% hypertonic saline solution mouthwash
Number of subjects: 60
Study 24637282 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular tooth brushing
Number of subjects: 60
Study 24637282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 22881048 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate comparison of procedures
Number of subjects: 198
Study 22881048 — intervention group
Group type: COMPARATOR
Intervention: Delayed exposure to multiple procedures without comparison
Number of subjects: 198
Study 22881048 — intervention group
Group type: COMPARATOR
Intervention: Delayed exposure to multiple procedures with comparison
Number of subjects: 198
Study 19422079 — intervention group
Group type: EXPERIMENTAL
Intervention: Open arm with capnographic monitoring
Number of subjects: 263
Study 19422079 — intervention group
Group type: COMPARATOR
Intervention: Blinded arm without capnographic monitoring
Number of subjects: 263
Study 17954173 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic color image analysis for quantification of interstitial fibrosis (IF) on routine renal biopsy.
Number of subjects: 26
Study 17954173 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine levels at 3 years post-transplantation.
Number of subjects: 26
Study 15516172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal halitosis measurement using a portable sulfide monitor
Number of subjects: 24
Study 15516172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral halitosis measurement using a portable sulfide monitor
Number of subjects: 24
Study 11825344 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir
Number of subjects: 13
Study 11825344 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 13
Study 9828635 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy radiation for occult CNV (n = 12)
Number of subjects: 57
Study 9828635 — intervention group
Group type: COMPARATOR
Intervention: Control group for occult CNV (n = 13)
Number of subjects: 57
Study 9828635 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy radiation for classic CNV (n = 18)
Number of subjects: 57
Study 9828635 — intervention group
Group type: COMPARATOR
Intervention: Control group for classic CNV (n = 14)
Number of subjects: 57
Study 9828635 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 Gy radiation
Number of subjects: 57
Study 9828635 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy radiation
Number of subjects: 57
Study 7654113 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (quitters)
Number of subjects: 2684
Study 7654113 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (smokers)
Number of subjects: 2684
Study 3202338 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium (0.03 mg.kg‐1)
Number of subjects: 53
Study 3202338 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.04 mg.kg‐1)
Number of subjects: 53
Study 3202338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.01 mg.kg‐1)
Number of subjects: 53
Study 3202338 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐tubocurarine (0.05 mg.kg‐1)
Number of subjects: 53
Study 3202338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.01 mg.kg‐1)
Number of subjects: 53
Study 31839310 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS-BA
Number of subjects: 0
Study 31839310 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS-GA
Number of subjects: 0